Outcomes of long-term responders to anti-programmed death 1 and anti-programmed death ligand 1 when being rechallenged with the same anti-programmed death 1 and anti-programmed death ligand 1 at progression-Reference-Cited by-同舟云学术

Outcomes of long-term responders to anti-programmed death 1 and anti-programmed death ligand 1 when being rechallenged with the same anti-programmed death 1 and anti-programmed death ligand 1 at progression

Published:2018-09 Issue: Volume:101 Page:160-164
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Bernard-Tessier A.,Baldini C.,Martin Patricia,Champiat Stéphane,Hollebecque Antoine,Postel-Vinay Sophie,Varga Andrea,Bahleda Rastilav,Gazzah Anas,Michot Jean-Marie^ORCID,Ribrag Vincent,Armand Jean-Pierre,Marabelle Aurélien,Soria Jean-Charles,Massard C.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference22 articles.

1. CT001 Durable, long-term survival in previously treated patients with advanced melanoma who received nivolumab monotherapy in a phase I trial;Hodi;Cancer Res,2016

2. Five-year follow-up of nivolumab in previously treated advanced non-small-cell lung cancer: results from the CA209-003 study;Gettinger;J Clin Oncol Off J Am Soc Clin Oncol,2018

3. Overall survival and long-term safety of nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non–small-cell lung cancer;Gettinger;J Clin Oncol Off J Am Soc Clin Oncol,2015

4. Long-term outcomes in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in the phase 3 KEYNOTE-006 study who completed pembrolizumab (pembro) treatment;Robert;J Clin Oncol Off J Am Soc Clin Oncol,2017

5. Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies;Lebbe;Ann Oncol,2014

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of cross‐line anti‐programmed death 1/programmed cell death‐ligand 1 antibody in the treatment of advanced nonsmall cell lung cancer: A retrospective study;Health Science Reports;2024-05

2. Retreatment with Immune Checkpoint Inhibitors in the New Scenario of Immunotherapy in Non-Small Cell Lung Cancer;Cancers;2024-04-26

3. Efficacy and safety analysis of immune checkpoint inhibitor rechallenge therapy in locally advanced and advanced non-small cell lung cancer: a retrospective study;Journal of Thoracic Disease;2024-03

4. Hyperprogressive disease under anti-PD-1 rechallenge after initial response to anti-PD-1 treatment for non-small cell lung cancer: a case report;Translational Lung Cancer Research;2024-03

5. Rechallenge of immune checkpoint inhibitors in advanced non‐small cell lung cancer;Thoracic Cancer;2024-01-14